On November 11, 2024, Aditxt, through its subsidiary Adivir, and Appili Therapeutics entered into a Mutual Waiver, extending the acquisition agreement's Outside Date to December 15, 2024. This follows a series of amendments to the original Arrangement Agreement, initially signed on April 1, 2024, which outlines Adivir's acquisition of all Appili shares.The acquisition will proceed under a statutory plan of arrangement, with Appili shareholders receiving a combination of Aditxt shares and cash. The transaction is contingent upon Aditxt securing at least $20 million in financing. The companies have agreed to waive any termination rights until December 15, 2024, and Adivir has paid a $115,000 waiver fee to Appili.Financial statements for Appili as of September 30, 2024, have been filed, showing a net loss of $2.3 million for the six months ended. The transaction aims to address Appili's liquidity challenges and is expected to close by December 2024, subject to customary conditions and approvals.

On November 11, 2024, Aditxt, through its subsidiary Adivir, and Appili Therapeutics entered into a Mutual Waiver, extending the acquisition agreement's Outside Date to December 15, 2024. This follows a series of amendments to the original Arrangement Agreement, initially signed on April 1, 2024, which outlines Adivir's acquisition of all Appili shares.The acquisition will proceed under a statutory plan of arrangement, with Appili shareholders receiving a combination of Aditxt shares and cash. The transaction is contingent upon Aditxt securing at least $20 million in financing. The companies have agreed to waive any termination rights until December 15, 2024, and Adivir has paid a $115,000 waiver fee to Appili.Financial statements for Appili as of September 30, 2024, have been filed, showing a net loss of $2.3 million for the six months ended. The transaction aims to address Appili's liquidity challenges and is expected to close by December 2024, subject to customary conditions and approvals.